A Non-Interventional Study of Rheumatoid Arthritis Patients Treated With RoActemra/Actemra (Tocilizumab) in Monotherapy

Sponsor
Hoffmann-La Roche
Study ID
NCT01705730
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • tocilizumab — DRUG
    Participants received tocilizumab monotherapy according to individualized physician-prescribed regimens.

Study Details

This observational study will evaluate the use and efficacy of RoActemra/Actemra (tocilizumab) in monotherapy in routine clinical practice in participants with rheumatoid arthritis. Eligible participants initiated on RoActemra/Actemra treatment according to the licensed label will be followed for 6 months.

Key Dates

Start date
Jul 31, 2012
Status verified
Aug 2018
Primary completion
Dec 12, 2014
Completion
Dec 12, 2014

Study Design

Enrollment
71 participants (actual)

Arms

  • Arm: Tocilizumab
    Participants with rheumatoid arthritis (RA) received tocilizumab monotherapy according to individualized physician-prescribed regimens.

Primary Outcome Measure

Percentage of Participants on Tocilizumab Treatment at Month 6 After Treatment Initiation [ Time Frame: Month 6 after treatment initiation ]

Related Studies